Effects of alpha-linolenic acid versus those of EPA/DHA on cardiovascular risk markers in healthy elderly subjects

Eur J Clin Nutr. 2006 Aug;60(8):978-84. doi: 10.1038/sj.ejcn.1602408. Epub 2006 Feb 15.

Abstract

Objective: To compare the effects of alpha-linolenic acid (ALA, C18:3n-3) to those of eicosapentaenoic acid (EPA, C20:5n-3) plus docosahexaenoic acid (DHA, C22:6n-3) on cardiovascular risk markers in healthy elderly subjects.

Design: A randomized double-blind nutritional intervention study.

Setting: Department of Human Biology, Maastricht University, the Netherlands.

Subjects: Thirty-seven mildly hypercholesterolemic subjects, 14 men and 23 women aged between 60 and 78 years.

Interventions: During a run-in period of 3 weeks, subjects consumed an oleic acid-rich diet. The following 6 weeks, 10 subjects remained on the control diet, 13 subjects consumed an ALA-rich diet (6.8 g/day) and 14 subjects an EPA/DHA-rich diet (1.05 g EPA/day + 0.55 g DHA/day).

Results: Both n-3 fatty acid diets did not change concentrations of total-cholesterol, LDL-cholesterol, HDL-cholesterol, triacylglycerol and apoA-1 when compared with the oleic acid-rich diet. However, after the EPA/DHA-rich diet, LDL-cholesterol increased by 0.39 mmol/l (P = 0.0323, 95% CI (0.030, 0.780 mmol/l)) when compared with the ALA-rich diet. Intake of EPA/DHA also increased apoB concentrations by 14 mg/dl (P = 0.0031, 95% CI (4, 23 mg/dl)) and 12 mg/dl (P = 0.005, 95% CI (3, 21 mg/dl)) versus the oleic acid and ALA-rich diet, respectively. Except for an EPA/DHA-induced increase in tissue factor pathway inhibitor (TFPI) of 14.6% (P = 0.0184 versus ALA diet, 95% CI (1.5, 18.3%)), changes in markers of hemostasis and endothelial integrity did not reach statistical significance following consumption of the two n-3 fatty acid diets.

Conclusions: In healthy elderly subjects, ALA might affect concentrations of LDL-cholesterol and apoB more favorably than EPA/DHA, whereas EPA/DHA seems to affect TFPI more beneficially.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Apolipoprotein A-I / blood
  • Cardiovascular Diseases / blood*
  • Cholesterol / blood*
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Docosahexaenoic Acids / blood
  • Docosahexaenoic Acids / pharmacology
  • Double-Blind Method
  • Eicosapentaenoic Acid / blood
  • Eicosapentaenoic Acid / pharmacology
  • Fatty Acids, Omega-3 / blood
  • Fatty Acids, Omega-3 / pharmacology*
  • Female
  • Humans
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / diet therapy*
  • Lipoproteins / blood*
  • Lipoproteins / drug effects
  • Male
  • Middle Aged
  • Oleic Acid / pharmacology
  • Risk Factors
  • Treatment Outcome
  • Triglycerides / blood
  • alpha-Linolenic Acid / blood
  • alpha-Linolenic Acid / pharmacology*

Substances

  • Apolipoprotein A-I
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Fatty Acids, Omega-3
  • Lipoproteins
  • Triglycerides
  • lipoprotein-associated coagulation inhibitor
  • alpha-Linolenic Acid
  • Docosahexaenoic Acids
  • Oleic Acid
  • Cholesterol
  • Eicosapentaenoic Acid